Ion Beam Applications SA IBA ( (GB:0GZK) ) has provided an update.
Ion Beam Applications S.A. (IBA) has signed a contract with the Asian Institute of Gastroenterology (AIG) in Hyderabad, India, to supply a Proteus®ONE compact proton therapy system. This marks the first installation of such a system in South Asia and represents a significant step for IBA in meeting the rising demand for proton therapy in India. The system will be part of AIG Hospitals’ new oncology center, aiming to start patient treatments by early 2028. This collaboration underscores IBA’s strategic positioning in the global market for advanced cancer treatment technologies, while AIG enhances its capabilities in providing state-of-the-art care.
More about Ion Beam Applications SA IBA
Ion Beam Applications S.A. (IBA) is a world leader in particle accelerator technologies and the foremost provider of proton therapy solutions for cancer treatment. The company is also involved in industrial sterilization, radiopharmaceuticals, and dosimetry. Headquartered in Louvain-la-Neuve, Belgium, IBA employs approximately 2,000 people worldwide and is listed on the EURONEXT stock exchange.
YTD Price Performance: 0.15%
Average Trading Volume: 1,272
Technical Sentiment Consensus Rating: Sell
Current Market Cap: €395.6M
For detailed information about 0GZK stock, go to TipRanks’ Stock Analysis page.